/ ASCO Briefing Room 2025
The Breast Cancer Briefing Room - ASCO 2025
Outcomes4Me in partnership with CURE brings you access to exclusive, hand-selected coverage of ASCO abstracts, sessions and key data specific to Breast Cancer, curated with scientific excellence and a patient-first perspective.
Articles
Bone is the most common site for breast cancer to spread when it becomes metastatic....
Palliative care for metastatic breast cancer: What you need to know Palliative care is a...
Integrative oncology for breast cancer: Managing HER2 treatment side effects If you’ve been diagnosed with...
Recent advancements have brought attention to a specific group of breast cancers called “HER2-low.” These...
The power of exercise after HER2-positive breast cancer If you’ve been diagnosed with HER2-positive breast...
From targeted therapies to managing side effects, this year’s American Society of Clinical Oncology (ASCO)...
Safety outcomes with first-line treatment of Enhertu (fam-trastuzumab deruxtecan-nxki; T-DXd) plus Perjeta (pertuzumab) is comparable...
Enhertu (fam-trastuzumab deruxtecan-nxki or T-DXd) has shown promising results in slowing down or stopping the...
